May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Valsartan Preserves Neuronal-Glial-Vascular Relationships in Retinopathy of Prematurity (ROP)
Author Affiliations & Notes
  • L. E. Downie
    The University of Melbourne, Parkville, Australia
    Department of Anatomy and Cell Biology,
    Department of Optometry and Vision Sciences,
  • M. J. Pianta
    The University of Melbourne, Parkville, Australia
    Department of Optometry and Vision Sciences,
  • A. J. Vingrys
    The University of Melbourne, Parkville, Australia
    Department of Optometry and Vision Sciences,
  • J. L. Wilkinson-Berka
    Department of Immunology, Monash University, Prahran, Australia
  • E. L. Fletcher
    The University of Melbourne, Parkville, Australia
    Department of Anatomy and Cell Biology,
  • Footnotes
    Commercial Relationships L.E. Downie, None; M.J. Pianta, None; A.J. Vingrys, None; J.L. Wilkinson-Berka, None; E.L. Fletcher, None.
  • Footnotes
    Support This work was supported by the National Health and Medical Research Council of Australia (NHMRC grant #350434 to E. L. F. and #350224 to A. J. V, and #299974 to J. W-B. & E. L. F.)
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4047. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. E. Downie, M. J. Pianta, A. J. Vingrys, J. L. Wilkinson-Berka, E. L. Fletcher; Valsartan Preserves Neuronal-Glial-Vascular Relationships in Retinopathy of Prematurity (ROP). Invest. Ophthalmol. Vis. Sci. 2007;48(13):4047.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: ROP is a retinal vaso-proliferative disorder affecting premature infants. This study has characterized neuronal and glial dysfunction relative to eccentricity-based changes in the vasculature in ROP. We also assessed the effect of angiotensin II type 1 receptor (AT1R) antagonism upon retinal pathology.

Methods:: ROP was induced in Sprague Dawley rats by exposure to 80±2% oxygen from postnatal (P) days 0-11, then 7 days room air. Controls were raised in room air. The AT1R antagonist valsartan (40mg/kg/day, intraperitoneal) was given to one group of control and ROP rats from P12-P18. Two further groups of control and ROP pups were sham injected (Tris Buffer, pH=8); n=6-8 per group. The vascular response was assessed by counting blood vessel profiles and by immunocytochemical localization of the endothelial cell marker isolectin-B4and the pericyte marker desmin. Glia were evaluated using glial fibrillary acidic protein, S100ß and EAAT4. Post-embedding immunocytochemistry was used to compare amino acid neurochemistry in neurons and glia.

Results:: ROP induced major changes to all retinal elements. The periphery was most affected, with a reduction in intraretinal blood vessels, intra-vitreal neovascularization, altered pericyte-endothelial interactions, reduced inner retinal thickness, neurochemical anomalies in amacrine and bipolar cells, astrocyte degeneration and Müller cell gliosis. In the mid-periphery we defined a "transition zone" in which local inner retinal blood vessels protected retinal integrity. At P18, valsartan-treated ROP pups had significantly reduced pathological neovascularization, improved physiological vascularization, more astrocytes and increased inner retinal thickness (ANOVA p<0.05) compared with shams.

Conclusions:: This study reveals complexity in the relationship of neuronal and glial cells to the vasculature in ROP. AT1R-signalling blockade suppressed pathological angiogenesis and protected peripheral neurons and glia. These findings support therapeutic approaches that alter signalling via the renin-angiotensin system in proliferative retinopathies.

Keywords: retinopathy of prematurity • retinal neovascularization • glia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×